-
Pomegranate top broken stomach! No one dares to do the surgery Zhejiang expert clever hand removal, this pomegranate is actually...
Time of Update: 2020-10-12
In the examination of Lin Dabo, Zhejiang University Hospital hematology experts carefully reviewed other hospitals on Lin Dabo's abdominal lumps made pathological laboratory reports, to determine that Lin Dabo is likely to suffer from a very rare blood disease - castleman disease.
-
Vertex and CRISPR Therapeutics' sickle cell gene therapy has been awarded the PRIME title.
Time of Update: 2020-10-12
CRISPR/Cas9 gene therapy CTX001 from Vertex Pharmaceuticals and CRISPR Therapeutics has been awarded the European Medicines Agency's Priority Drug (PRIME) title for the treatment of severe sickle cell disease (SCD).
prime title will speed up the development plan and evaluation of the CTX001.
-
Blood: Machine learning reveals the correlation between MDS genotypes and morphological characteristics.
Time of Update: 2020-10-12
study used machine learning techniques to identify symbic patterns between morphological features and genomic events to analyze new clinical subsequencies of MDS.
study sequenced 1,079 MDS patients and analyzed bone marrow morphological changes and other clinical features.
-
The world's first AIDS cure, "Berlin Patient" leukemia relapse.
Time of Update: 2020-10-12
Inception, Brown was called a "Berlin patient" at a medical conference to remain anonymous, but in 2010 he decided to open his identity to the world, giving speeches, giving interviews, insisting on assisting scientists in AIDS treatment research, and creating the Timothy Ray Brown Foundation, the World AIDS Institute, in the hope of helping more people with AIDS.
-
J Clin Oncol: Optimize the treatment of chisellular antigens T-cells in adult patients with acute lymphoblastic leukemia.
Time of Update: 2020-10-12
low-dose queue (n s 9) to receive single or sub-drug, toxicity controlled, complete remission (CR) rate of 33%.
20 patients in a high dose d'ivy (HDF) queue had a CR rate of 90% and CRS was controlled.
-
Lancet haematol: The efficacy of Vibutosi monoantigen anti-combined Navuliyu monoantitherapy for elderly patients with Hodgkin's lymphoma.
Time of Update: 2020-10-12
mid-term analysis on 11 October 2019, the overall remission rate of the first 25 patients assessed was 64% (16/25), of which 13 (52%) received full metabolic remission and 3 (12%) received partial metabolic remission.
of all assessable patients (46), 22 (48%) received complete metabolic remission and 6 (13%) received partial metabolic remission (overall remission rate of 61%).
-
Blood: CD19 targets the prognostication and related factors of secondary infusion of CAR T cells for the treatment of incurable B-cell malignant tumors.
Time of Update: 2020-10-12
patients who received Cy-Flu lymphatic removal prior to CART1 and had a higher dose of CART2 than CART1 had better durability of CAR T cells after CART2.
-
CAR-T Cell Therapy MB-102 Treatment BPDCN, AML, hrMDS: Multi-Center Phase I/II clinical trials are to be conducted.
Time of Update: 2020-10-12
Biology company Mustang recently announced that the first patient has been treated with drugs in a multi-center Phase I/II clinical trial to evaluate MB-102 (CAR-T cell therapy for CD123) to treat recurring recurring recurring recurring resuscious maternal plasma cell-like dendioblast tumors (BPDCN), acute myeloid leukemia (AML) and high-risk myeloid proliferative syndrome (hrMDS).
-
Lancet Haematol: CD20 monoantigen obinutuzumab combined with DHAP to treat the efficacy of suite cell lymphoma.
Time of Update: 2020-10-12
, obinutuzumab combined with DHAP is well-to-resistant for transplantable sleeve lymphoma and has good activity in inducing micro-residual lesions negative.
obinutuzumab combined with DHAP as an induced chemotherapy has potential activity, and a negative bone marrow micro-residual lesions may predict long-term disease control.
-
FDA Awards CAR-T Cancer Therapy CLBR001 and SWI019 "Fast Track Title"
Time of Update: 2020-10-12
The FDA has awarded Calibr the new "switchable" CAR-T cell therapy CLBR001 and SWI019 "fast track title" to accelerate drug development and review.
Calibr's "switchable" CAR-T cell therapy combines an antibody called SWI019, which can act as a "switch" to activate engineered cells (CLBR001) and guide them to bind to cancer targets.
-
Blood: Mutation characteristics of gray lymphoma!
Time of Update: 2020-10-12
studied 50 EBV-negative GZL and 20 EBV-positive polymorphic DLBCL NOS (Poly-EBV-L) code sequence mutations and compared them with classic Hodgkin's lymphoma (CHL), primary longitudinal large B-cell lymphoma (PMBCL) and diffuse large B-cell lymphoma (DLBCL).
-
medRxiv: The world's first PD1 knockout virus-targeted integrated CART treatment for lymphoma has achieved breakthrough results.
Time of Update: 2020-10-04
("Bangyao Bio"), a company focused on gene therapy and cell drug research and development, announced a breakthrough in the clinical trial of "PD1 Knockout Virus Point Integration CD19-CART Cell Therapy Recurring Non-Hodgkin's Lymphoma" in collaboration with the First Hospital affiliated with Zhejiang University Medical College.
-
Japan's Ministry of Health, Labour and Labour approves ravulizumab treatment for atypical hemolytic uremia syndrome (aHUS) in adults and children
Time of Update: 2020-10-04
in many cases, aHUS patients may have poor prognosis, with 56 per cent of adults and 29 per cent of children receiving supportive treatment alone developing end-stage kidney disease or death within a year.
-
Blood: Pomadamine treats hormone incurable chronic grafts against host disease.
Time of Update: 2020-10-04
Curtis, etc., conducted a random phase 2 clinical trial to determine the safety, effectiveness, and preferred dose of Pomalidomide in patients with moderate-severe cGVHD who are insensitive to glucosticoids and/or follow-up treatments.
8 subjects in the 2 mg group were treated with dose reduction due to adverse reactions.
-
Blood: Acute GVHD can be prevented with IRX4204-targeted vending acid nuclei.
Time of Update: 2020-10-04
(Survival of mice treated differently after transplantation) Thangavelu and others found that IRX4204 was better at preventing acute graft anti-host disease (GVHD) in vivo than FK506 (tekmos, used to prevent transplant rejection after liver and kidney transplantation); IRX4204 after transplantation can reduce intestinal damage and reduce serum interferon-gamma and tumor necrosis factor-alpha levels.
-
Blood: Targeting cytokine checkpoints enhances the adaptability of cord blood CAR-NK cells.
Time of Update: 2020-10-03
cytokine inhibitor signal family protein plays an important role in physiological activity and anti-tumor toxicity of NK cells.
in order to extend the clinical effects of checkpoint targeting, Daher and others have designed a joint strategy to combine lecytocyte interlethional (IL)-15-CAR engineering with NK cells that knock out the source of CISH's cord blood (CB).
-
And Platinum Pharmaceuticals presented its BCMAxCD3 dual-specific antibodies at the Cell Engager Summit this year after completing a $75 million B-plus and a $100 million round of C-round financing.
Time of Update: 2020-10-03
HBM7020 can overcome certain limitations and become a new generation therapy for multiple myeloma, selectively removing BCMA-positive MM cells and having less cytokine release.
HBM7020 effectively kills BCMA-positive MM cells and reduces the risk of CRS (cytokine release syndrome) compared to competitor Regeneron's BCMAxCD3 dual-specific antibodies.
-
Blood: The effect of anticoagulant therapy on the prognosis of thrombosis in visceral veins.
Time of Update: 2020-10-03
results of this study show that anticoagulant therapy can improve SVT recombment without increasing haemorrhage, while reducing the risk of thrombosis progression.
-
Blood: Early diagnosis of heparin-induced plate plate plate reduction!
Time of Update: 2020-10-03
classified as "HIT-uncertain" were considered disease-negative in the initial analysis and positive in the sensitivity analysis.
, PEA is a technically simple non-radioactive detection method that uses about 20 times less plateplates than SRA and is highly accurate in the diagnosis of HIT.
-
Lancet oncol: Comparison of the efficacy of kafazomi with boronitzomi in the treatment of multiple myeloma.
Time of Update: 2020-10-03
trial was a multicenter, open-label Phase 3 randomized controlled trial that recruited newly diagnosed patients over the age of 18 with multiple myeloma who were unsuitable or did not intend to perform ASCT directly, randomly assigned to the KRd or VRd group at 1:1 for 36 weeks of treatment.
